(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36020 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Onconova Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 22-3627252 (State or other jurisdiction of (I.R ...

Table of Contents For the transition period from to Commission file number 001-36020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark one) ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Onconova Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other j ...

Financial Performance - Net losses for the nine months ended September 30, 2021, were $12.4 million compared to $18.7 million for the same period in 2020, with an accumulated deficit of $441.0 million as of September 30, 2021[110]. - Revenue for the three months ended September 30, 2021, was $57,000, a decrease of $9,000 compared to $66,000 in the same period of 2020[150]. - The net loss for the three months ended September 30, 2021, was $3,453,000, an improvement of $2,788,000 from a net loss of $6,241,000 in the same period of 2020[150]. - Revenues decreased by $9,000, or 14%, for the three months ended September 30, 2021, compared to the same period in 2020[151]. - Net cash used in operating activities was $15.2 million for the nine months ended September 30, 2021, compared to $17.6 million for the same period in 2020[170]. - Net cash provided by financing activities was $55.6 million for the nine months ended September 30, 2021, compared to $19.1 million for the same period in 2020[175]. - The accumulated deficit at September 30, 2021, was $441.0 million[168]. Cash and Financing - As of September 30, 2021, the company had $59.4 million in cash and cash equivalents, expected to fund operations and ongoing trials for more than two years[114]. - The company raised approximately $8.5 million from a common stock offering on January 12, 2021, and approximately $26.7 million from another offering on February 16, 2021[111]. - An at-the-market equity distribution agreement was entered on August 20, 2021, allowing for the sale of up to $25.0 million in common stock, with net proceeds of approximately $0.5 million from 109,523 shares sold by September 30, 2021[112]. - The company is exploring various funding sources for ongoing operations and development, emphasizing the need for additional financing to continue its clinical-stage programs[115]. - The company expects net cash expenditures in 2022 to be comparable to 2021, primarily due to ongoing clinical trials[177]. Research and Development - Narazaciclib (ON 123300) is a multi-kinase inhibitor targeting CDK4/6 and other tyrosine kinases, showing potential efficacy in various cancers[107]. - The IC50 values for narazaciclib against CDK4 and CDK6 are 3.87 nM and 9.82 nM, respectively, indicating its potency compared to palbociclib[118]. - A collaboration agreement with HanX for the development and commercialization of narazaciclib in China includes upfront payments, milestone payments, and royalties on future sales[122]. - The IND for narazaciclib was approved by the Chinese FDA on January 6, 2020, following a filing by HanX in the fourth quarter of 2019[124]. - Enrollment in the US Phase 1 study of narazaciclib commenced in May 2021, with 36 patients enrolled in the first cohort, showing no dose limiting toxicities[125]. - A complementary Phase 1 study for narazaciclib in China has been initiated, with the first patient enrolled on September 15, 2020, and no dose limiting toxicities observed to date[126]. - Narazaciclib is expected to provide preliminary safety data and the recommended Phase 2 dose and schedule upon completion of the Phase 1 studies[127]. - The safety profile of narazaciclib is anticipated to be similar to approved CDK4/6 inhibitors, with common adverse events including myelosuppression and gastrointestinal toxicity[137]. - Preliminary efficacy data from a study of rigosertib in combination with a PD-1 inhibitor in KRAS-mutated NSCLC showed a clinical benefit rate of 43%[141]. Operating Expenses - Total operating expenses for the three months ended September 30, 2021, were $4,047,000, down by $2,293,000 from $6,340,000 in the same period of 2020[150]. - Research and development expenses decreased by $2,430,000 to $1,763,000 for the three months ended September 30, 2021, compared to $4,193,000 in 2020[150]. - General and administrative expenses increased by $0.8 million, or 12%, to $7.4 million for the nine months ended September 30, 2021, from $6.5 million for the same period in 2020[161]. - Research and development expenses decreased by $6.8 million, or 55%, to $5.6 million for the nine months ended September 30, 2021, from $12.4 million for the same period in 2020[163]. - The change in fair value of warrant liability increased by $474,000, from $56,000 in 2020 to $530,000 in 2021[150]. - The fair value of the warrant liability decreased by $0.3 million for the nine months ended September 30, 2021, compared to an increase of $0.1 million for the same period in 2020[165].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36020 Onconova Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 22-3627252 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 12 Penns Trail, Newtown, PA 18940 (Address of principal executive offices) (Zip Cod ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36020 Onconova Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 22-3627252 (State or other jurisdiction of (I.R.S. Employer incor ...

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36020 Onconova Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other j ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36020 Onconova Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer incorporation or orga ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36020 Onconova Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 22-3627252 (State or other jurisdiction of (I.R.S. Employer incorp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36020 Onconova Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 22-3627252 (State or other jurisdiction of (I.R.S. Employer incorporation or organizat ...

Use these links to rapidly review the document TABLE OF CONTENTS ONCONOVA THERAPEUTICS, INC. AND SUBSIDIARIES Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark one) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36020 ...